A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Grant Support Bookmark and Share

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator

Grant Support

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator
Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • Traditionally, blood donation comes with perks – tokens such as a gift certificate, swag emblazoned with the donor center’s logo or the occasional movie ticket. Kasie Uyeno, manager of Blood Donor Recruitment for City of Hope, knows that’s not what brings donors back to the center again and again. T...
  • Anyone who tours City of Hope will almost certainly be taken by two key buildings: City of Hope Helford Clinical Research Hospital and the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology. The heart of the campus, in more ways than one, the two buildings are a stone’s t...
  • In June 2012, 28-year-old Emily Bennett Taylor was getting ready to celebrate her second wedding anniversary with her college sweetheart when she discovered that she had Stage 4 lung cancer. Taylor was a former college athlete, had led a healthy and active lifestyle and had never smoked. She quickly began treat...
  • “Skin cancer” was pretty much the last thing on the mind of a healthy, outdoorsy kid like Tanner Harbin. “I like hockey – playing it and watching it,” the 23-year-old from San Dimas said. “I like to go off-roading with my dad – we have a Jeep and we have a cabin up in Big Bear, so […]
  • Skin cancer is an enticing field to be in these days. Just ask Laleh Melstrom, M.D. M.S., one of City of Hope’s newest surgeons. “In the last few years, melanoma has been the type of cancer that has really shown the most progress in terms of treatments,” Melstrom said. “It’s the one cancer in 2015 that is...
  • Skin cancer is the most common type of cancer in the United States today, and its incidence is on the rise. Forty to 50 percent of light-skinned Americans who live to age 65 will have skin cancer at least once in their lives. Most of these skin cancers – about 3.5 million cases – are the […]
  • The connection between lifestyle and cancer is real. Knowing that, what can individuals do to lower their risk? City of Hope physicians recently came together to answer that precise question, explaining the links between cancer and the choices we make that affect our health. Moderator Vijay Trisal M.D., medical...
  • White button mushrooms seem fairly innocuous as fungi go. Unlike portabellas, they don’t center stage at the dinner table, and unlike truffles, they’re not the subject of gourmand fervor. But appearances can be deceiving when it comes to these mild-mannered Clark Kents of the food world. In a study ...
  • Doctors often recommend preventive screenings for several cancers, based on hereditary or genetic factors, but brain tumors aren’t one of them. Primary brain tumors, which originate in the brain rather than spreading from another location, seem to develop at random, and doctors have little insight into wh...
  • Stopping cancer starts with research. To that end, STOP CANCER has awarded $525,000 in grants to City of Hope for 2015, supporting innovative research projects and recognizing the institution’s leadership in advancing cancer treatment and prevention. Founded in 1988, STOP CANCER underwrites the work of le...
  • Cancer may not be the disease many people think it is. Normally, cancer is considered to be a disease in which cells multiply at an extremely high, and unusual, rate – increasing the likelihood of genetic mutations. But increasingly, leading researchers at City of Hope and elsewhere are contending that cancer i...
  • “Of all forms of inequality, injustice in the health care system is the most shocking and inhumane.” By the time the Rev. Martin Luther King Jr. spoke those words in Chicago in 1966, the Civil Rights Act had been passed, the Voting Rights Act was the law of the land and the March on Washington was […]
  • Eight years ago, Matthew Loscalzo surprised himself by accepting the offer to become City of Hope’s administrative director of the Sheri & Les Biller Patient and Family Resource Center and executive director of the Department of Supportive Care Medicine. At the time, he was administrative director of the Sc...
  • The mental fog that patients can experience after undergoing chemotherapy treatment for cancer has a name: “chemo brain.” “Many patients report hearing or reading about chemotherapy-related cognitive deficits, but few are actually prepared to deal with these changes,” said Celina Lemon, M.A., an occupational th...
  • Cancer treatments have improved over the years, but one potential source of treatments and cures remains largely untapped: nature. Blueberries, cinnamon, xinfeng, grape seed (and skin) extract, mushrooms, barberry and pomegranates all contain compounds with the potential to treat or prevent cancer. Scientists a...